FDA Approves BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE — Amneal Pharmaceuticals of New York, LLC

Amneal Pharmaceuticals’ recent FDA approval for the generic version of butalbital/aspirin/caffeine/codeine phosphate positions the company to capture market share now that the brand drug’s patents have expired. This approval enhances Amneal’s portfolio, introducing a more affordable oral alternative for patients managing migraine and tension headaches.